Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSS67 SAD Study in Healthy Adult Participants
NCT07487545Phase 1Not yet recruiting
- Sponsor
- 3SBio
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of SSS67 in obesity, Sarcopenia and osteoporosis (6 arms), sponsored by 3SBio. Primary endpoint: Incidence and severity of Adverse Events at Day 57. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SSS67
03
Conditions
obesitySarcopeniaosteoporosis
Beyond the preview
Go deeper on NCT07487545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487545.